PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 28410959-3 2017 The effect of fluvoxamine augmentation on BDNF-CREB pathways in peripheral mononuclear cells (PMC s) of medicated schizophrenia patients was also studied. Fluvoxamine 14-25 brain derived neurotrophic factor Homo sapiens 42-46 16522641-12 2006 We found that the BDNF-stimulated PLC-gamma activation and the ensued increase in intracellular Ca2+ ([Ca2+]i) were potentiated by pretreatment with imipramine or fluvoxamine, so was the BDNF-induced glutamate release. Fluvoxamine 163-174 brain derived neurotrophic factor Homo sapiens 18-22 16522641-12 2006 We found that the BDNF-stimulated PLC-gamma activation and the ensued increase in intracellular Ca2+ ([Ca2+]i) were potentiated by pretreatment with imipramine or fluvoxamine, so was the BDNF-induced glutamate release. Fluvoxamine 163-174 brain derived neurotrophic factor Homo sapiens 187-191 31180700-0 2020 BDNF association study with obsessive-compulsive disorder, its clinical characteristics, and response to fluvoxamine-treatment in Iranian patients. Fluvoxamine 105-116 brain derived neurotrophic factor Homo sapiens 0-4 28410959-7 2017 In the clinic, PMC s of treated patients showed upregulation of mRNA expression and protein levels of BDNF, CREB and AKT after addition of fluvoxamine. Fluvoxamine 139-150 brain derived neurotrophic factor Homo sapiens 102-106 25756551-2 2015 Recent evidence from animal and clinical studies that adding fluvoxamine to antipsychotics alters the expression of transcripts encoding for the GABA-A receptor and BDNF led us to postulate that fluvoxamine augmentation may improve memory in schizophrenia. Fluvoxamine 61-72 brain derived neurotrophic factor Homo sapiens 165-169 25756551-2 2015 Recent evidence from animal and clinical studies that adding fluvoxamine to antipsychotics alters the expression of transcripts encoding for the GABA-A receptor and BDNF led us to postulate that fluvoxamine augmentation may improve memory in schizophrenia. Fluvoxamine 195-206 brain derived neurotrophic factor Homo sapiens 165-169 17092970-0 2007 The G196A polymorphism of the brain-derived neurotrophic factor gene and the antidepressant effect of milnacipran and fluvoxamine. Fluvoxamine 118-129 brain derived neurotrophic factor Homo sapiens 30-63 17092970-2 2007 The purpose of the present study was to investigate whether the G196A polymorphism of the brain-derived neurotrophic factor (BDNF) gene is associated with the antidepressant effect of milnacipran, a serotonin norepinephrine reuptake inhibitor, and fluvoxamine, a selective serotonin reuptake inhibitor. Fluvoxamine 248-259 brain derived neurotrophic factor Homo sapiens 90-123 17092970-2 2007 The purpose of the present study was to investigate whether the G196A polymorphism of the brain-derived neurotrophic factor (BDNF) gene is associated with the antidepressant effect of milnacipran, a serotonin norepinephrine reuptake inhibitor, and fluvoxamine, a selective serotonin reuptake inhibitor. Fluvoxamine 248-259 brain derived neurotrophic factor Homo sapiens 125-129 17092970-7 2007 In all subjects receiving milnacipran or fluvoxamine, the G/A genotype of the BDNF G196A polymorphism was associated with a significantly better therapeutic effect in the MADRS scores during this study. Fluvoxamine 41-52 brain derived neurotrophic factor Homo sapiens 78-82 17092970-9 2007 These results suggest that the BDNF G196A polymorphism in part determines the antidepressant effect of both milnacipran and fluvoxamine. Fluvoxamine 124-135 brain derived neurotrophic factor Homo sapiens 31-35 25089150-1 2014 BACKGROUND: We investigated the association between serum proBDNF, a precursor of brain-derived neurotrophic factor (BDNF), and response to fluvoxamine in patients with major depressive disorder (MDD) using the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR): physically healthy and free of current alcohol or drug abuse, comorbid anxiety, or personality disorders. Fluvoxamine 140-151 brain derived neurotrophic factor Homo sapiens 82-115 25089150-1 2014 BACKGROUND: We investigated the association between serum proBDNF, a precursor of brain-derived neurotrophic factor (BDNF), and response to fluvoxamine in patients with major depressive disorder (MDD) using the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR): physically healthy and free of current alcohol or drug abuse, comorbid anxiety, or personality disorders. Fluvoxamine 140-151 brain derived neurotrophic factor Homo sapiens 61-65 21179660-7 2010 In addition, responders to fluvoxamine, paroxetine, milnacipran, and sertraline all increased serum BDNF levels. Fluvoxamine 27-38 brain derived neurotrophic factor Homo sapiens 100-104